Scarica l'app Stockscreener
122.43
1.32%
1.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$121.25
Aprire:
$121.26
Volume 24 ore:
2.71M
Relative Volume:
0.44
Capitalizzazione di mercato:
$212.98B
Reddito:
$43.84B
Utile/perdita netta:
$13.90B
Rapporto P/E:
15.36
EPS:
7.9725
Flusso di cassa netto:
$6.92B
1 W Prestazione:
-1.94%
1M Prestazione:
-2.41%
6M Prestazione:
-8.41%
1 anno Prestazione:
+6.37%
Intervallo 1D:
$120.70
$123.03
Intervallo di 1 settimana:
$120.70
$126.05
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
122.48 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.20 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.22 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.36 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.99 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Rep. Richard Dean Dr McCormick Has Bought Up to $390K Worth Of Abbott Laboratories Stock: Here's What You Should Know - Benzinga
Vanguard Group Inc's Strategic Acquisition of Abbott Laboratories Shares - GuruFocus
Investment Management Corp of Ontario Sells 32,347 Shares of Abbott Laboratories $ABT - MarketBeat
Ossiam Has $8.77 Million Position in Abbott Laboratories $ABT - MarketBeat
Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns - Yahoo Finance
Daiwa Securities Group Inc. Has $37.79 Million Position in Abbott Laboratories $ABT - MarketBeat
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott (ABT) Expands Lingo Glucose Monitor to Android Users - GuruFocus
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - AOL.com
Abbott (NYSE: ABT) adds Lingo to Android, cites 15% lower odds of glucose spikes - Stock Titan
SVB Wealth LLC Has $12.17 Million Stake in Abbott Laboratories $ABT - MarketBeat
Divergent Views Emerge on Abbott Laboratories’ Stock Valuation - AD HOC NEWS
The Minnesotan behind Cologuard, which fueled the biggest health care acquisition of 2025 - Star Tribune
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives - Finviz
Abbott (ABT) awards $1 million as Big Ten drive logs 83,043 blood donations - Stock Titan
Seaview Investment Managers LLC Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - MSN
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Is Abbott Laboratories Fairly Priced After Growth In Devices And Diagnostics? - Yahoo Finance
FDA Warning For Abbott Glucose Sensors After 700 Injuries, 7 DeathsAbbott Laboratories (NYSE:ABT) - Benzinga
Healthtech Market Is Booming Worldwide With Boston Scientific, Philips Healthcare, Abbott Laboratories, - EIN News
Guggenheim Capital LLC Buys 11,794 Shares of Abbott Laboratories $ABT - MarketBeat
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley - Yahoo Finance
Arrowstreet Capital Limited Partnership Purchases 291,987 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Diabetes Glucose Monitors Recalled After 7 Deaths and More Than 700 Injuries - People.com
Top Analyst Reports for HSBC, Abbott & Shell - Yahoo Finance
Medtronic launches new diabetes tech integrated with Abbott sensor - Cardiovascular Business
FDA Issues Warning on Abbott (ABT) Glucose Monitors After Reported Deaths - GuruFocus
How Abbott Laboratories (ABL) stock trades after rate cuts2025 Trade Ideas & Fast Exit and Entry Trade Guides - Newser
Faulty Glucose Monitor Sensors May Be Tied to 7 Deaths, F.D.A. Says - The New York Times
Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - marketscreener.com
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and MoreResearchAndMarkets.com - The AI Journal
Muscles, the New Flex: Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - Finviz
Abbott (NYSE: ABT) debuts Ensure Max Protein 42g, 2 in 1 shakes with Walmart rollout - Stock Titan
Panagora Asset Management Inc. Trims Stake in Abbott Laboratories $ABT - MarketBeat
Millions of Abbott Glucose Sensors Recalled After Faulty Readings Linked to Deaths - The Suburban
Abbott - The Pharma Letter
Don't Ignore The Insider Selling In Abbott Laboratories - simplywall.st
Abbott Laboratories $ABT Stake Lifted by First Trust Advisors LP - MarketBeat
Baird Financial Group Inc. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Medtronic launches insulin delivery system with Abbott-made sensor - MedTech Dive
Abbott Laboratories' (NYSE:ABT) Price Is Right But Growth Is Lacking - 富途牛牛
Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups - USA Herald
Abbott Defends Glucose Monitor Patents In Sinocare Fight - Law360
Abbott Laboratories (NYSE: ABT) sees Vanguard report 10.05% beneficial stake - Stock Titan
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock - sharewise.com
7 deaths, hundreds of injuries may be linked to diabetes glucose monitor errors, FDA says - CBS News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
M&T Bank Corp Trims Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):